Treatment of verrucous carcinoma with recombinant alfa-interferon.

Abstract

BACKGROUND:

Verrucous carcinoma is an uncommon neoplasm whose medical treatment is not well defined.

OBJECTIVE:

We report the clinical effects of recombinant alpha-interferon (IFN) with varying dispensing routes on the tumor size in 3 patients exhibiting three different subtypes of verrucous carcinoma.

OBSERVATIONS:

In case 1, an oral florid papillomatosis of the upper gingiva, a stabilization of the lesion size was observed after the administration of a cumulative dose of 45 million IU of IFN alfa-2b. The patient died after discontinuation of the treatment due to hepatic toxicity. In case 2, a giant condyloma acuminatum of the penis, treatment with a cumulative dose of 522 million IU of IFN alfa-2a first resulted in stabilization of the disease, and no evidence of recurrence was observed after surgical treatment. In case 3, a verrucous carcinoma of the leg, a mild decrease in lesion size was observed after the administration of a cumulative dose of 174 million IU. Surgery was finally required.

CONCLUSION:

In reducing the growth of the tumor, treatment by IFN appears to be an adjuvant therapy of verrucous carcinoma, but it never prevents surgery or death.

• Authors: L Risse, P Négrier, P M Dang, C Bedane, P Bernard, F Labrousse, J M Bonnetblanc
• Journal: Dermatology (Basel, Switzerland) (Dermatology) Vol. 190 Issue 2 Pg. 142-4 ( 1995) ISSN: 1018-8665 [Print] Switzerland
• PMID: 7727836 (Publication Type: Case Reports, Journal Article)

Chemical References

• Interferon-alpha

Topics

• Aged
• Carcinoma, Verrucous (surgery, therapy)
• Combined Modality Therapy
• Condylomata Acuminata (surgery, therapy)
• Fatal Outcome
• Female
• Follow-Up Studies
• Gingival Neoplasms (therapy)
• Humans
• Interferon-alpha (administration & dosage, therapeutic use)
• Male
• Middle Aged
• Papilloma (therapy)
• Penile Neoplasms (surgery, therapy)
• Skin Neoplasms (surgery, therapy)